To evaluate the effects of microRNA-21 (miR-21) in peripheral blood mononuclear cells (PBMC) in the diagnosis and prognosis of prostate cancer (PCa).
METHODS:
Proved by pathologic biopsy, 92 patients diagnosed with PCa and also underwent resection operation and 85 patients with benign prostatic hyperplasia (BPH) were selected in this study, as well as 97 healthy volunteers were chosen as the control group. PBMC were extracted to examine the relative expression of miR-21 by real time reverse transcriptase-polymerase chain reaction (RT-PCR). The relative operating characteristic (ROC) curves were drew to analyze the diagnosis value of PCa. The survival function curves were made by Kaplan-Meier method to show the miR-21 expression levels of PCa patients. The Log-rank test was adopted to compare the differences among the different groups. The Cox proportional hazard risk regression analysis was used to screen the independent factors affected the PCa patients.
RESULTS:
The expression levels of miR-21 in PCa group were increased compared to BPH and control group (P < 0.05). The expression of miR-21 was significantly correlated with the Gleason score, clinical stages, bone metastasis and tumor recurrence (all P < 0.05). ROC curves demonstrated that the area under the curve of PCa and BPH distinguished by the miR-21 were 0.974 and 95% confidence intervals (95% CI) were 0.956∼ 0.993. The sensitivity and specificity were 93.5% and 92.9%. ROC curves demonstrated that the area under the curve of PCa and control group distinguished by the miR-21 were 0.984 and 95% CI were 0.972∼ 0.997. The sensitivity and specificity were 94.6% and 92.8%. The results of Kaplan-Meier Method demonstrated that the miR-21 expression levels were related to the prognosis of PCa (all P < 0.05). The results of the COX analysis suggested that the miR-21 expression level, tumor recurrence and bone metastasis could be the independent factors affected the prognosis of PCa patients (all P < 0.05).
CONCLUSION:
miR-21 is highly expressed in the PCa patients, which could be the molecule biomarker of diagnosis and prognosis of PCa.
HeidenreichA., BellmuntJ., BollaM., JoniauS., MasonM., MatveevV., MottetN., SchmidH.P., van der KwastT., WiegelT., ZattoniF. and European Association of Urology, EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease, Eur Urol59 (2011), 61-71.
2.
LeitzmannM.F. and RohrmannS., Risk factors for the onset of prostatic cancer: age, location, and behavioral correlates, Clin Epidemiol4 (2012), 1-11.
3.
FukushimaK., SatohT., BabaS. and YamashitaK., alpha1,2-Fucosylated and beta-N-acetylgalactosaminylated prostate-specific antigen as an efficient marker of prostatic cancer, Glycobiology20 (2010), 452-460.
4.
SbonerA., DemichelisF., CalzaS., PawitanY., SetlurS.R., HoshidaY., PernerS., AdamiH.O., FallK., MucciL.A., KantoffP.W., StampferM., AnderssonS.O., VarenhorstE., JohanssonJ.E., GersteinM.B., GolubT.R., RubinM.A. and AndrenO., Molecular sampling of prostate cancer: A dilemma for predicting disease progression, BMC Med Genomics3 (2010), 8.
5.
LapukA.V., WuC., WyattA.W., McPhersonA., McConeghyB.J., BrahmbhattS., MoF., ZoubeidiA., AndersonS., BellR.H., HaegertA., ShukinR., WangY., FazliL., Hurtado-CollA., JonesE.C., HachF., HormozdiariF., HajirasoulihaI., BoutrosP.C., BristowR.G., ZhaoY., MarraM.A., FanjulA., MaherC.A., ChinnaiyanA.M., RubinM.A., BeltranH., SahinalpS.C., GleaveM.E., VolikS.V. and CollinsC.C., From sequence to molecular pathology, and a mechanism driving the neuroendocrine phenotype in prostate cancer, J Pathol227 (2012), 286-297.
6.
ShenJ., HrubyG.W., McKiernanJ.M., GurvichI., LipskyM.J., BensonM.C. and SantellaR.M., Dysregulation of circulating microRNAs and prediction of aggressive prostate cancer, Prostate72 (2012), 1469-1477.
7.
BryantR.J., PawlowskiT., CattoJ.W., MarsdenG., VessellaR.L., RheesB., KuslichC., VisakorpiT. and HamdyF.C., Changes in circulating microRNA levels associated with prostate cancer, Br J Cancer106 (2012), 768-774.
8.
WangW., ZhangE. and LinC., MicroRNAs in tumor angiogenesis, Life Sci (2015).
9.
MishraS., DengJ.J., GowdaP.S., RaoM.K., LinC.L., ChenC.L., HuangT. and SunL.Z., Androgen receptor and microRNA-21 axis downregulates transforming growth factor beta receptor II (cancer, Oncogene33 (2014), 4097-4106.
10.
RibasJ. and LupoldS.E., The transcriptional regulation of miR-21, its multiple transcripts, and their implication in prostate cancer, Cell Cycle9 (2010), 923-929.
11.
GongC., YaoY., WangY., LiuB., WuW., ChenJ., SuF., YaoH. and SongE., Up-regulation of miR-21 mediates resistance to trastuzumab therapy for breast cancer, J Biol Chem286 (2011), 19127-19137.
12.
ZhengY., CuiL., SunW., ZhouH., YuanX., HuoM., ChenJ., LouY. and GuoJ., MicroRNA-21 is a new marker of circulating tumor cells in gastric cancer patients, Cancer Biomark10 (2011), 71-77.
13.
ReisS.T., Pontes-JuniorJ., AntunesA.A., Dall'OglioM.F., DipN., PasserottiC.C., RossiniG.A., MoraisD.R., NesrallahA.J., PiantinoC., SrougiM. and LeiteK.R., miR-21 may acts as an oncomir by targeting RECK, a matrix metalloproteinase regulator, in prostate cancer, BMC Urol12 (2012), 14.
14.
RibasJ., NiX., HaffnerM., WentzelE.A., SalmasiA.H., ChowdhuryW.H., KudrolliT.A., YegnasubramanianS., LuoJ., RodriguezR., MendellJ.T. and LupoldS.E., miR-21: An androgen receptor-regulated microRNA that promotes hormone-dependent and hormone-independent prostate cancer growth, Cancer Res69 (2009), 7165-7169.
15.
World Medical Association Inc., Declaration of Helsinki. Ethical principles for medical research involving human subjects, J Indian Med Assoc107 (2009), 403-405.
16.
MassengillJ.C., SunL., MoulJ.W., WuH., McLeodD.G., AmlingC., LanceR., FoleyJ., SextonW., KusudaL., ChungA., SoderdahlD. and DonahueT., Pretreatment total testosterone level predicts pathological stage in patients with localized prostate cancer treated with radical prostatectomy, J Urol169 (2003), 1670-1675.
17.
ZhangW., JiaoH., ZhangX., ZhaoR., WangF., HeW., ZongH., FanQ. and WangL., Correlation between the expression of dnmt1, and gstp1 and apc, and the methylation status of gstp1 and apc in association with their clinical significance in prostate cancer, Mol Med Rep12 (2015), 141-146.
18.
MitchellP.S., ParkinR.K., KrohE.M., FritzB.R., WymanS.K., Pogosova-AgadjanyanE.L., PetersonA., NoteboomJ., O'BriantK.C., AllenA., LinD.W., UrbanN., DrescherC.W., KnudsenB.S., StirewaltD.L., GentlemanR., VessellaR.L., NelsonP.S., MartinD.B. and TewariM., Circulating micrornas as stable blood-based markers for cancer detection, Proc Natl Acad Sci U S A105 (2008), 10513-10518.
19.
HunterM.P., IsmailN., ZhangX., AgudaB.D., LeeE.J., YuL., XiaoT., SchaferJ., LeeM.L., SchmittgenT.D., Nana-SinkamS.P., JarjouraD. and MarshC.B., Detection of microrna expression in human peripheral blood microvesicles, PLoS One3 (2008), e3694.
20.
JiangM., Guo-HaoG.U., ZhangJ. and ChenX., Expression of mir-21 in pbmc of patients with esophageal cancer[j], China Journal of Modern Medicine (2013).
21.
CollaresC.V., EvangelistaA.F., XavierD.J., RassiD.M., ArnsT., Foss-FreitasM.C., FossM.C., PuthierD., Sakamoto-HojoE.T., PassosG.A. and DonadiE.A., Identifying common and specific micrornas expressed in peripheral blood mononuclear cell of type 1, type 2, and gestational diabetes mellitus patients, BMC Res Notes6 (2013), 491.
22.
HuangW., KangX.L., CenS., WangY. and ChenX., High-level expression of microrna-21 in peripheral blood mononuclear cells is a diagnostic and prognostic marker in prostate cancer, Genet Test Mol Biomarkers19 (2015), 469-475.
23.
ShiG.H., YeD.W., YaoX.D., ZhangS.L., DaiB., ZhangH.L., ShenY.J., ZhuY., ZhuY.P., XiaoW.J. and MaC.G., Involvement of microRNA-21 in mediating chemo-resistance to docetaxel in androgen-independent prostate cancer PC3 cells, Acta Pharmacol Sin31 (2010), 867-873.
24.
Yaman AgaogluF., KovancilarM., DizdarY., DarendelilerE., HoldenriederS., DalayN. and GezerU., Investigation of miR-21, miR-141, and miR-221 in blood circulation of patients with prostate cancer, Tumour Biol32 (2011), 583-588.
25.
CastroB., SanchezP., TorresJ.M., PredaO., del MoralR.G. and OrtegaE., Bisphenol A exposure during adulthood alters expression of aromatase and 5alpha-reductase isozymes in rat prostate, PLoS One8 (2013), e55905.
26.
GoldsteinA.S., HuangJ., GuoC., GarrawayI.P. and WitteO.N., Identification of a cell of origin for human prostate cancer, Science329 (2010), 568-571.
27.
HeidenreichA., Identification of high-risk prostate cancer: Role of prostate-specific antigen, PSA doubling time, and PSA velocity, Eur Urol54 (2008), 976-977; discussion 978-979.
28.
WegielB., EvansS., HellstenR., OtterbeinL.E., BjartellA. and PerssonJ.L., Molecular pathways in the progression of hormone-independent and metastatic prostate cancer, Curr Cancer Drug Targets10 (2010), 392-401.
29.
SenthilkumarK., ArunkumarR., ElumalaiP., SharmilaG., GunadhariniD.N., BanudeviS., KrishnamoorthyG., BensonC.S. and ArunakaranJ., Quercetin inhibits invasion, migration and signalling molecules involved in cell survival and proliferation of prostate cancer cell line (PC-3), Cell Biochem Funct29 (2011), 87-95.
30.
TaoT., WangY., LuoH., YaoL., WangL., WangJ., YanW., ZhangJ., WangH., ShiY., YinY., JiangT., KangC., LiuN. and YouY., Involvement of FOS-mediated miR-181b/miR-21 signalling in the progression of malignant gliomas, Eur J Cancer49 (2013), 3055-3063.
31.
CleggN.J., WongvipatJ., JosephJ.D., TranC., OukS., DilhasA., ChenY., GrillotK., BischoffE.D., CaiL., AparicioA., DorowS., AroraV., ShaoG., QianJ., ZhaoH., YangG., CaoC., SensintaffarJ., WasielewskaT., HerbertM.R., BonnefousC., DarimontB., ScherH.I., Smith-JonesP., KlangM., SmithN.D., De StanchinaE., WuN., OuerfelliO., RixP.J., HeymanR.A., JungM.E., SawyersC.L. and HagerJ.H., ARN-509: A novel antiandrogen for prostate cancer treatment, Cancer Res72 (2012), 1494-1503.
32.
MorimuraR., KomatsuS., IchikawaD., TakeshitaH., TsujiuraM., NagataH., KonishiH., ShiozakiA., IkomaH., OkamotoK., OchiaiT., TaniguchiH. and OtsujiE., Novel diagnostic value of circulating miR-18a in plasma of patients with pancreatic cancer, Br J Cancer105 (2011), 1733-1740.
